| 1 |
Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article [J]. J Psychopharmacol, 2008, 22(2 Suppl): 12-19.
|
| 2 |
Marano RJ, Ben-Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions [J]. Mol Endocrinol, 2014, 28(5): 622-633.
|
| 3 |
Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease [J]. Nat Rev Endocrinol, 2019, 15(6): 356-365.
|
| 4 |
Ghoreshi ZA, Akbari H, Sharif-Zak M, et al. Recent findings on hyperprolactinemia and its pathological implications: A literature review [J]. J Investig Med, 2022, 70(7): 1443-1451.
|
| 5 |
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab, 2011, 96(2): 273-288.
|
| 6 |
中华医学会神经外科学分会, 中华医学会妇产科学分会, 中华医学会内分泌学分会. 高催乳素血症诊疗共识 [J]. 中华医学杂志, 2011, 91(3): 147-154.
|
| 7 |
Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: A pituitary society international consensus statement [J]. Nat Rev Endocrinol, 2023, 19(12): 722-740.
|
| 8 |
Macotela Y, Triebel J, Clapp C. Time for a new perspective on prolactin in metabolism [J]. Trends Endocrinol Metab, 2020, 31(4): 276-286.
|
| 9 |
Pirchio R, Graziadio C, Colao A, et al. Metabolic effects of prolactin [J]. Front Endocrinol(Lausanne), 2022, 13: 1015520.
|
| 10 |
Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, et al. The beneficial metabolic actions of prolactin [J]. Front Endocrinol (Lausanne), 2022, 13: 1001703.
|
| 11 |
Karaca Z, Unluhizarci K, Kelestimur F. Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus : “absence of proof is not the proof of absence” [J]. Rev Endocr Metab Disord, 2024, 25(6): 943-951.
|
| 12 |
Terra LF, Garay-Malpartida MH, Wailemann RA, et al. Recombinant human prolactin promotes human beta cell survival via inhibition of extrinsic and intrinsic apoptosis pathways [J]. Diabetologia, 2011, 54(6): 1388-1397.
|
| 13 |
Chien HY, Chen SM, Li WC. Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions [J]. Front Clin Diabetes Healthc, 2023, 4: 935872.
|
| 14 |
Auriemma RS, De Alcubierre D, Pirchio R, et al. Glucose abnormalities associated to prolactin secreting pituitary adenomas [J]. Front Endocrinol (Lausanne), 2019 10: 327.
|
| 15 |
Pirchio R, Auriemma RS, Solari D, et al. Effects of pituitary surgery and high-dose cabergoline therapy on metabolic profile in patients with prolactinoma resistant to conventional cabergoline treatment [J]. Front Endocrinol (Lausanne), 2021, 12: 769744.
|
| 16 |
Jiang XB, Li CL, He DS, et al. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: A pilot study [J]. Pituitary, 2014, 17(3): 232-239.
|
| 17 |
Tuzcu A, Yalaki S, Arikan S, et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique [J]. Pituitary, 2009, 12(4): 330-334.
|
| 18 |
Ponce AJ, Galván-Salas T, Lerma-Alvarado RM, et al. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans [J]. Endocrine, 2020, 67(2): 331-343.
|
| 19 |
Li J, Rice MS, Huang T, et al. Circulating prolactin concentrations and risk of type 2 diabetes in US women [J]. Diabetologia, 2018, 61(12): 2549-2560.
|
| 20 |
Faria de Castro L, Alves Dos Santos Á, Augusto Casulari L, et al. Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis [J]. Diabetes Res Clin Pract, 2020, 166: 108247.
|
| 21 |
Wang T, Lu J, Xu Y, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: A population-based study [J]. Diabetes Care, 2013, 36(7): 1974-1980.
|
| 22 |
Park S, Kim DS, Daily JW, et al. Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats [J]. Diabetes Metab Res Rev, 2011, 27(6): 564-574.
|
| 23 |
Bole-Feysot C, Goffin V, Edery M, et al. Prolactin(PRL)and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice [J]. Endocrine Reviews, 1998, 19(3): 225-268.
|
| 24 |
Freemark M, Avril I, Fleenor D, et al. Targeted deletion of the PRL receptor: Effects on islet development, insulin production, and glucose tolerance [J]. Endocrinology, 2002, 143(4): 1378-1385.
|
| 25 |
Balbach L, Wallaschofski H, Völzke H, et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? [J]. BMC endocrine disorders, 2013, 13: 12.
|
| 26 |
Daimon M, Kamba A, Murakami H, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men [J]. PloS One, 2017, 12(4): e0175204.
|
| 27 |
Sheoran A, Agarwal N, Mahto SK, et al. Study of association of serum prolactin levels with insulin resistance in type 2 diabetes mellitus patients [J]. Indian J Endocrinol Metab, 2023, 27(4): 351-356.
|
| 28 |
Lopez-Vicchi F, De Winne C, Brie B, et al. Metabolic functions of prolactin: Physiological and pathological aspects [J]. J Neuroendocrinol, 2020, 32(11): e12888.
|
| 29 |
Brandebourg TD, Bown JL, Ben-Jonathan N. Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue [J]. Biochem Biophys Res Commun, 2007, 357(2): 408-413.
|
| 30 |
Lopez-Vicchi F, De Winne C, Ornstein AM, et al. Severe hyperprolactinemia promotes brown adipose tissue whitening and aggravates high fat diet induced metabolic imbalance [J]. Front Endocrinol (Lausanne), 2022, 13: 883092.
|
| 31 |
Posawetz AS, Trummer C, Pandis M, et al. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study [J]. BMC Endocr Disord, 2021, 21(1): 81.
|
| 32 |
Baba MS, Laway BA, Misgar RA, et al. Metabolic abnormalities, inflammatory markers and endothelial dysfunction in hyperprolactinemia due to prolactinoma before and after normalization of serum prolactin: A prospective case control study [J]. Indian J Endocrinol Metab, 2023, 27(4): 357-364.
|
| 33 |
Ruiz-Herrera X, de Los Ríos EA, Díaz JM, et al. Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males [J]. Endocrinology, 2017, 158(1): 56-68.
|
| 34 |
Liu J, Wang Q, Zhang L, et al. Increased prolactin is an adaptive response to protect against metabolic disorders in obesity [J]. Endocr Pract, 2021, 27(7): 728-735.
|
| 35 |
Liu J, Zhang L, Fu J, et al. Circulating prolactin level is increased in metabolically healthy obesity [J]. Endocrine Connections, 2021, 10(4): 484-491.
|
| 36 |
Zhang P, Ge Z, Wang H, et al. Prolactin improves hepatic steatosis via CD36 pathway [J]. J Hepatol, 2018, 68(6): 1247-1255.
|